J&J Unit Settles Off-Label Marketing Claims For $81M

Law360, New York (April 29, 2010, 5:52 PM EDT) -- A unit of Johnson & Johnson has agreed to pay more than $81 million to put to rest a U.S. Department of Justice inquiry into off-label marketing of the epilepsy and migraine drug Topamax.

Under the agreement reached with the DOJ and other federal agencies, Ortho-McNeil-Janssen Pharmaceuticals Inc. will pay $75.37 million to settle allegations that the company improperly marketed Topamax for off-label psychiatric uses, causing false claims to be submitted to government health care programs such as Medicaid that do not cover those uses of...
To view the full article, register now.